CONMED Corp. announced its intent to exit its gastroenterology product lines as part of a strategy to optimize its portfolio.

The exit, the company said, lets it fully align operations and resources in its core markets of minimally invasive, robotic, and laparoscopic surgery, smoke evacuation, and the surgical treatment of orthopedic soft tissue repair.

“Today’s announcement reflects a positive step in our strategic portfolio review and our commitment to focus on areas where CONMED can lead in innovation and deliver the greatest impact—minimally invasive surgery, smoke evacuation, and orthopedic soft tissue repair,” said Patrick J. Beyer, CONMED’s president and CEO.

The company’s gastroenterology products are anticipated to garner $90 million of revenue this year, with about 45% gross margins. The company expects EPS dilution of $0.45–$0.55 next year due to the strategic exit.

CONMED holds exclusive U.S. and Canadian distribution rights for the Gore Viabil biliary stent thanks to an agreement with W.L. Gore & Associates. CONMED didn’t plan to renew this agreement beyond December 31, 2026 per its latest 10-Q filing, but after strategic review decided to conclude the agreement effective January 1, 2026. The company plans to use the proceeds from the Gore transaction for strategic investments, debt paydown, and share repurchases.

“By concentrating our resources on our core growth platforms, we are positioning CONMED for long-term success and continued leadership in surgical innovation,” said Beyer. “We are proud of the contributions our gastroenterology team has made to advancing patient care and supporting clinicians over the years, and we thank them for their dedication and impact on the business.”

The company doesn’t expect a material impact on 2025 financial results, and reaffirmed its prior guidance range for revenue ($1.365-1.372 billion) and adjusted EPS ($4.48-4.53).